600713 Stock Overview
Engages in the pharmaceutical wholesale and retail businesses in China.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 4/6 |
NanJing Pharmaceutical Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥4.90 |
| 52 Week High | CN¥5.82 |
| 52 Week Low | CN¥3.85 |
| Beta | 0.41 |
| 1 Month Change | 4.93% |
| 3 Month Change | n/a |
| 1 Year Change | -11.07% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -9.09% |
Recent News & Updates
Recent updates
Shareholder Returns
| 600713 | CN Healthcare | CN Market | |
|---|---|---|---|
| 7D | -0.4% | -1.0% | 0.03% |
| 1Y | -11.1% | -30.6% | -10.2% |
Return vs Industry: 600713 exceeded the CN Healthcare industry which returned -30.6% over the past year.
Return vs Market: 600713 matched the CN Market which returned -10.2% over the past year.
Price Volatility
| 600713 volatility | |
|---|---|
| 600713 Average Weekly Movement | 2.6% |
| Healthcare Industry Average Movement | 5.3% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in CN Market | 10.7% |
| 10% least volatile stocks in CN Market | 4.2% |
Stable Share Price: 600713 has not had significant price volatility in the past 3 months.
Volatility Over Time: 600713's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1951 | 4,903 | Liang Zhang | www.njyy.com |
NanJing Pharmaceutical Company Limited engages in the pharmaceutical wholesale and retail businesses in China. It also operates various pharmacies and an e-commerce platform. The company was founded in 1951 and is based in Nanjing, China.
NanJing Pharmaceutical Company Limited Fundamentals Summary
| 600713 fundamental statistics | |
|---|---|
| Market cap | CN¥6.42b |
| Earnings (TTM) | CN¥587.75m |
| Revenue (TTM) | CN¥53.46b |
10.9x
P/E Ratio0.1x
P/S RatioIs 600713 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600713 income statement (TTM) | |
|---|---|
| Revenue | CN¥53.46b |
| Cost of Revenue | CN¥50.13b |
| Gross Profit | CN¥3.33b |
| Other Expenses | CN¥2.75b |
| Earnings | CN¥587.75m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.45 |
| Gross Margin | 6.24% |
| Net Profit Margin | 1.10% |
| Debt/Equity Ratio | 138.6% |
How did 600713 perform over the long term?
See historical performance and comparison